Microsoft is rolling out a major overhaul of its Windows Insider Program, aiming to simplify how early Windows features are tested while addressing long-standing user complaints around complexity and ...

Connecticut prosecutors and police chiefs have put the brakes on the rapidly expanding acquisition by police agencies of artificial intelligence-powered law enforcement tools until the emerging ...

This project provides common data structures and algorithms with clean, expressive, and reusable abstractions — bringing a modern programming experience to C. It includes implementations of widely ...

A hot potato: GitHub has announced that starting April 24, the company will begin using interaction data from Copilot Free, Pro, and Pro+ users to train and improve its AI models unless they opt out.

This story is part of a Seattle Times focus on the affordability crisis in the Northwest. We explore the high cost of living and wealth disparities that shape our region; examine policies that impact ...

File - In this Tuesday, Oct. 5, 2021, photo, a woman stands at her well at her property on the outskirts of The Dalles, Oregon. She said the water table that her well draws from dropped 15 feet in the ...

Starlink says it may also share personal data with partners to help it "develop AI-enabled tools that improve your customer experience.” Joe Supan is a senior writer for CNET covering home technology, ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Abstract: Multiple programming tasks require synchronous collaboration between developers, giving rise to real-time collaborative programming tools that enable ...

Driven by the artificial intelligence frenzy, Microsoft is internally projecting that water use at its data centers will more than double by 2030 from 2020, including in places that face shortages.

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...